SANTA CRUZ, Calif., Oct. 1, 2024 /PRNewswire/ — Fullpower-AI®, in collaboration with Stanford University and UCSF, is proud to announce the results of a landmark study presented at the recent European Sleep Conference in Seville, Spain. This study, leveraging the Sleeptracker-AI® platform, represents the largest-ever population-based assessment of sleep duration and architecture, analyzing over 7 million nights of sleep data.
Key Findings are:
Age-Specific Insights:
“This study provides crucial baseline data for understanding sleep patterns across the lifespan and the impact of sleep disorders,” said Philippe Kahn, Founder and CEO of Fullpower-AI®. “It underscores the importance of the 7-hour sleep recommendation and highlights how conditions like sleep apnea can significantly impact sleep quality.”
The scale and depth of this research mark a significant advancement in sleep science. These findings may shape future research and clinical practice in sleep medicine.
For more information about the study or to access detailed data, please visit sleeptracker.com.
About Fullpower-AI®
Fullpower-AI® designs, develops, and operates the Sleeptracker-AI® platform worldwide, targeting clinical trials and medical practitioners. Integrated into market-leading Tempur-Pedic smart beds, our platform offers clinical-grade accuracy comparable to gold-standard PSG.
For further details or media inquiries, contact busdev@fullpower.com
SOURCE Fullpower
12 Month Timeline - How Cannabis Rescheduling Actually Takes EffectAnnouncementPresident signals intent or issues executive…
First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel…
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- TrialWire®, the industry’s fastest, intelligent patient recruitment…
The skilled nursing, assisted and senior living provider reiterates dedication to a financial restructuring process…
MARKHAM, Ontario, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX:…
TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and…